InflaRx (IFRX) Enterprise Value (2016 - 2026)
InflaRx (IFRX) posted Enterprise Value of -$46.6 million for Q1 2026, up 13.84% sequentially from -$54.1 million in Q4 2025, and up 6.79% YoY from -$43.6 million in Q1 2025.
InflaRx (IFRX) Enterprise Value (2016 - 2026) Analysis & Trends
InflaRx has reported Enterprise Value for 11 years, with the latest figure at -$46.6 million in Q1 2026.
- Quarterly Enterprise Value rose 6.79% year-over-year to -$46.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.6 million (up 6.79% YoY) and the FY2025 annual result came in at -$52.5 million, up 8.26% from the prior year.
- Enterprise Value rose to -$46.6 million in Q1 2026 per IFRX's latest filing, from -$54.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$10.8 million in Q1 2023 and troughed at -$101.0 million in Q1 2022.
- A 5-year average of -$40.2 million and a median of -$41.9 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 89.31% in 2023, then slumped 177.44% in 2024.
- Over 5 years, Enterprise Value stood at -$19.6 million in 2022, then fell by 20.06% to -$23.5 million in 2023, then tumbled by 140.6% to -$56.5 million in 2024, then rose by 4.27% to -$54.1 million in 2025, then gained by 13.84% to -$46.6 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$46.6 million, -$54.1 million, and -$52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 2.12 Bn |
| 10 | InflaRx | 142.18 Mn | -42.07 Mn | 2.74 Bn | -184.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.60 Mn |
| Dec 31, 2025 | -54.08 Mn |
| Sep 30, 2025 | -52.19 Mn |
| Jun 30, 2025 | -54.33 Mn |
| Mar 31, 2025 | -49.99 Mn |
| Dec 31, 2024 | -56.49 Mn |
| Sep 30, 2024 | -63.58 Mn |
| Jun 30, 2024 | -20.88 Mn |
| Mar 31, 2024 | -29.98 Mn |
| Dec 31, 2023 | -23.48 Mn |
| Sep 30, 2023 | -23.88 Mn |
| Jun 30, 2023 | -41.89 Mn |
| Mar 31, 2023 | -10.80 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -18.37 Mn |
| Jun 30, 2022 | -16.70 Mn |
| Mar 31, 2022 | -101.03 Mn |
| Dec 31, 2021 | -61.15 Mn |
| Sep 30, 2021 | -34.74 Mn |
| Jun 30, 2021 | -153.18 Mn |